Cool site pour acheter des pilules http://achetermedicaments2014.com/ Ne pas se perdre venir sur.
The official text of the Prohibited List
shall be maintained by WADA
and shall be published in English and French. In the event of any conflict between the English and French versions, the English version shall prevail.
This List shall come into effect on 1 January 2013-
The 2013 Prohibited List 10 September 2012
THE 2013 PROHIBITED LIST
WORLD ANTI-DOPING CODE
Valid 1 January 2013
In accordance with Article 4.2.2 of the World Anti-Doping Code,
all Prohibited Substances
shall be considered as “Specified Substances” except Substances in classes S1, S2, S4.4, S4.5, S6.a, and Prohibited Methods
M1, M2 and M3.
SUBSTANCES AND METHODS PROHIBITED AT ALL TIMES
(IN- AND OUT-OF-COMPETITION)
S0. NON-APPROVED SUBSTANCES
Any pharmacological substance which is not addressed by any of the
subsequent sections of the List and with no current approval by any
governmental regulatory health authority for human therapeutic use (e.g
drugs under pre-clinical or clinical development or discontinued, designer
drugs, substances approved only for veterinary use) is prohibited at all
times. S1. ANABOLIC AGENTS
Anabolic agents are prohibited. 1. Anabolic Androgenic Steroids (AAS)
a. Exogenous* AAS, including:
(5α-androst-1-ene-3β,17β-diol ); 1-androstenedione
(estr-4-ene-3β,17β-diol ); bolasterone;
17β-ol); drostanolone; ethylestrenol
fluoxymesterone; formebolone; furazabol
methyl[1,2,5]oxadiazolo[3',4':2,3]-5α-androstan-17β-ol); gestrinone; 4-
mesterolone; metenolone; methandienone
methylandrosta-1,4-dien-3-one); methandriol; methasterone
4-en-3-one); methyltestosterone; metribolone
hydroxy-17α-methylestra-4,9,11-trien-3-one); mibolerone; nandrolone; 19-
(estr-4-ene-3,17-dione); norboletone; norclostebol;
norethandrolone; oxabolone; oxandrolone; oxymesterone; oxymetholone;
androstane); quinbolone; stanozolol; stenbolone; 1-testosterone
and other substances with a similar chemical structure or
similar biological effect(s).
b. Endogenous** AAS when administered exogenously:
(dehydroepiandrosterone, DHEA, 3β-hydroxyandrost-5-en-17-one);
and their metabolites and isomers, including but not limited to: 5α-androstane-3α,17α-diol; 5α-androstane-3α,17β-diol; 5α-androstane-
3β,17α-diol; 5α-androstane-3β,17β-diol; androst-4-ene-3α,17α-diol;
androst-4-ene-3α,17β-diol; androst-4-ene-3β,17α-diol; androst-5-ene-
3α,17α-diol; androst-5-ene-3α,17β-diol; androst-5-ene-3β,17α-diol;
ene-3,17-dione); epi-dihydrotestosterone; epitestosterone;
etiocholanolone; 3α-hydroxy-5α-androstan-17-one; 3β-hydroxy-5α-
androstan-17-one; 7α-hydroxy-DHEA ; 7β-hydroxy-DHEA ; 7-keto-DHEA;
2. Other Anabolic Agents, including but not limited to:
Clenbuterol, selective androgen receptor modulators (SARMs), tibolone,
* “exogenous” refers to a substance which is not ordinarily capable of being
produced by the body naturally.
** “endogenous” refers to a substance which is capable of being produced by the
S2. PEPTIDE HORMONES, GROWTH FACTORS AND RELATED
The following substances and their releasing factors are prohibited:
1. Erythropoiesis-Stimulating Agents [
e.g. erythropoietin (EPO),
darbepoetin (dEPO), hypoxia-inducible factor (HIF) stabilizers,
methoxy polyethylene glycol-epoetin beta (CERA), peginesatide
2. Chorionic Gonadotrophin (CG) and Luteinizing Hormone (LH)
4. Growth Hormone (GH), Insulin-like Growth Factor-1 (IGF-1),
Fibroblast Growth Factors (FGFs), Hepatocyte Growth Factor (HGF),
Mechano Growth Factors (MGFs), Platelet-Derived Growth Factor
(PDGF), Vascular-Endothelial Growth Factor (VEGF)
as well as any
other growth factor affecting muscle, tendon or ligament protein
synthesis/degradation, vascularisation, energy utilization, regenerative
capacity or fibre type switching;
and other substances with similar chemical structure or similar biological effect(s). S3. BETA-2 AGONISTS
All beta-2 agonists, including all optical isomers (e.g. d-
) where relevant, are prohibited except inhaled salbutamol (maximum 1600 micrograms over 24 hours), inhaled formoterol (maximum delivered dose 54 micrograms over 24 hours) and salmeterol when taken by inhalation in accordance with the manufacturers’ recommended therapeutic regimen. The presence in urine of salbutamol in excess of 1000 ng/mL or formoterol in excess of 40 ng/mL is presumed not to be an intended therapeutic use of the substance and will be considered as an Adverse Analytical Finding
unless the Athlete
proves, through a controlled pharmacokinetic study, that the abnormal result was the consequence of the use of the therapeutic inhaled dose up to the maximum indicated above.
S4. HORMONE AND METABOLIC MODULATORS
The following are prohibited: 1. Aromatase inhibitors
including, but not limited to: aminoglutethimide,
(androstatrienedione), 4-androstene-3,6,17 trione (6-oxo),
exemestane, formestane, letrozole, testolactone.
2. Selective estrogen receptor modulators (SERMs)
including, but not
limited to: raloxifene, tamoxifen, toremifene.
3. Other anti-estrogenic substances
including, but not limited to:
clomiphene, cyclofenil, fulvestrant.
4. Agents modifying myostatin function(s)
including, but not limited, to:
5. Metabolic modulators:
b) Peroxisome Proliferator Activated Receptor δ (PPARδ) agonists
(e.g. GW 1516), PPARδ-AMP-activated protein kinase (AMPK) axis
agonists (e.g. AICAR)
S5. DIURETICS AND OTHER MASKING AGENTS
Masking agents are prohibited. They include: Diuretics, desmopressin, plasma expanders (
administration of albumin, dextran, hydroxyethyl starch
and other substances with similar biological effect(s).
Local administration of felypressin in dental anaesthesia is not prohibited.
Diuretics include: Acetazolamide, amiloride, bumetanide, canrenone, chlorthalidone,
etacrynic acid, furosemide, indapamide, metolazone, spironolactone,
e.g. bendroflumethiazide, chlorothiazide, hydrochlorothiazide),
; and other substances with a similar chemical structure or similar
biological effect(s) (except drospirenone, pamabrom and topical dorzolamide and
brinzolamide, which are not prohibited).
The use In-
as applicable, of any quantity of a substance
subject to threshold limits (i.e. formoterol, salbutamol, cathine, ephedrine,
methylephedrine and pseudoephedrine) in conjunction with a diuretic or other
masking agent requires the deliverance of a specific Therapeutic Use Exemption
for that substance in addition to the one granted for the diuretic or other masking
M1. MANIPULATION OF BLOOD AND BLOOD COMPONENTS
The following are prohibited:
1. The administration or reintroduction of any quantity of autologous,
homologous or heterologous blood or red blood cell products of any origin into the circulatory system.
2. Artificially enhancing the uptake, transport or delivery of oxygen, including,
but not limited to, perfluorochemicals, efaproxiral (RSR13) and modified haemoglobin products (e.g. haemoglobin-based blood substitutes, microencapsulated haemoglobin products), excluding supplemental oxygen.
3. Any form of intravascular manipulation of the blood or blood components by
M2. CHEMICAL AND PHYSICAL MANIPULATION
The following are prohibited:
or attempting to tamper, in order to alter the integrity and
validity of Samples
collected during Doping Control
. These include but are not limited to urine substitution and/or adulteration (e.g. proteases).
2. Intravenous infusions and/or injections of more than 50 mL per 6 hour period
except for those legitimately received in the course of hospital admissions or clinical investigations.
M3. GENE DOPING
The following, with the potential to enhance sport performance, are prohibited:
1. The transfer of polymers of nucleic acids or nucleic acid analogues;
2. The use of normal or genetically modified cells.
SUBSTANCES AND METHODS
In addition to the categories S0 to S5 and M1 to M3 defined above,
the following categories are prohibited In-Competition:
All stimulants, including all optical isomers (e.g. d-
) where relevant, are prohibited, except imidazole derivatives for topical use and those stimulants included in the 2013 Monitoring Program*.
a: Non-Specified Stimulants: Adrafinil; amfepramone; amiphenazole; amphetamine; amphetaminil;
benfluorex; benzphetamine; benzylpiperazine; bromantan; clobenzorex;
cocaine; cropropamide; crotetamide; dimethylamphetamine;
etilamphetamine; famprofazone; fencamine; fenetylline; fenfluramine;
fenproporex; furfenorex; mefenorex; mephentermine; mesocarb;
modafinil; norfenfluramine; phendimetrazine; phenmetrazine;
phentermine; 4-phenylpiracetam (carphedon); prenylamine; prolintane.
A stimulant not expressly listed in this section is a Specified Substance.
b: Specified Stimulants (examples): Adrenaline**; cathine***; ephedrine****; etamivan; etilefrine; fenbutrazate;
fencamfamin; heptaminol; isometheptene; levmetamfetamine;
meclofenoxate; methylephedrine****; methylhexaneamine
(dimethylpentylamine); methylphenidate; nikethamide; norfenefrine;
octopamine; oxilofrine (methylsynephrine); parahydroxyamphetamine;
pemoline; pentetrazol; phenpromethamine; propylhexedrine;
pseudoephedrine*****; selegiline; sibutramine; strychnine;
and other substances with a similar chemical structure or
* The following substances included in the 2013 Monitoring Program (bupropion, caffeine, nicotine, phenylephrine, phenylpropanolamine, pipradol, synephrine) are not considered as Prohibited Substances
** Local administration (e.g. nasal, ophthalmologic) of Adrenaline
administration with local anaesthetic agents is not prohibited.
is prohibited when its concentration in urine is greater than 5
**** Each of ephedrine
is prohibited when its
concentration in urine is greater than 10 micrograms per milliliter.
is prohibited when its concentration in urine is greater
than 150 micrograms per milliliter.
The following are prohibited:
Buprenorphine, dextromoramide, diamorphine (heroin), fentanyl and its
derivatives, hydromorphone, methadone, morphine, oxycodone,
oxymorphone, pentazocine, pethidine.
Natural (e.g. cannabis, hashish, marijuana) or synthetic delta 9-
tetrahydrocannabinol (THC) and cannabimimetics (e.g. “Spice”, JWH018,
JWH073, HU-210) are prohibited. S9. GLUCOCORTICOSTEROIDS
All glucocorticosteroids are prohibited when administered by oral, intravenous,
intramuscular or rectal routes.
SUBSTANCES PROHIBITED IN PARTICULAR
Alcohol (ethanol) is prohibited In-Competition
only, in the following sports.
Detection will be conducted by analysis of breath and/or blood. The doping
violation threshold (haematological values) is 0.10 g/L. • Aeronautic (FAI)
Unless otherwise specified, beta-blockers are prohibited In-Competition
the following sports.
• Archery (FITA) (also prohibited Out-of-Competition
• Shooting (ISSF, IPC) (also prohibited Out-of-Competition
• Skiing/Snowboarding (FIS) in ski jumping, freestyle aerials/halfpipe and
Beta-blockers include, but are not limited to, the following: Acebutolol, alprenolol, atenolol, betaxolol, bisoprolol, bunolol, carteolol,
carvedilol, celiprolol, esmolol, labetalol, levobunolol, metipranolol,
metoprolol, nadolol, oxprenolol, pindolol, propranolol, sotalol, timolol.
The Effects of Vitamin D Deficiency in Athletes Michael E. Angeline, Albert O. Gee, Michael Shindle, Russell F. Warren and Scott A. RodeoThe online version of this article can be found at: can be found at: The American Journal of Sports Medicine Additional services and information for Michael E. Angeline,* MD, Albert O. Gee,* MD, Michael Shindle,y MD,Russell F. Warren,* MD, an
King to Pay $124 Mln to Settle Fraud Claim, U.S. Says (Update2) 2005-11-01 17:05 (New York) (Adds company comment on SEC probe in 12th paragraph.) By Cary O'Reilly Nov. 1 (Bloomberg) -- King Pharmaceuticals Inc., the maker of drugs including Altace heart pills, agreed to pay $124 million to settle claims it overcharged Medicaid programs for its products. The Bristol, Tennessee-based company underp